Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

RegulatoryCardiologyHeart Pump DevicesSafety Signal

Abiomed Issues Update on Automated Impella Controllers Due to Software Error

The software error in Abiomed's Automated Impella Controllers poses a significant safety risk, potentially undermining user trust and market position. This situation necessitates close monitoring of regulatory responses and communication strategies to address stakeholder concerns.

Published: June 29, 2026
Updated: June 29, 2026
Author: Humanexa Intelligence
Therapeutic area: Cardiology / Heart Pump Devices
Asset: Abiomed
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval

Asset

Abiomed

Indication

Cardiology / Heart Pump Devices

Status

Under Review

Signal Score

8.4

Signal assessment

Signal strength

high

Confidence level

high

Signalhigh
Confidencehigh

Strategic implication

The software error in Abiomed's Automated Impella Controllers poses a significant safety risk, potentially undermining user trust and market position. This situation necessitates close monitoring of regulatory responses and communication strategies to address stakeholder concerns.

Why it matters

The software error in Abiomed's Automated Impella Controllers poses a significant safety risk, potentially undermining user trust and market position. This situation necessitates close monitoring of regulatory responses and communication strategies to address stakeholder concerns.

What changed

Safety Signal

Analysis

A software error may cause the Automated Impella Controller to restart when used with left ventricular Impella devices.

The software error in Abiomed's Automated Impella Controllers poses a significant safety risk, potentially undermining user trust and market position. This situation necessitates close monitoring of regulatory responses and communication strategies to address stakeholder concerns.

Monitor for further updates from Abiomed regarding the resolution of the software issue and any regulatory actions.

Related companies & assets

Assets

  • Abiomed →

Sources & Humanexa intelligence

Source links

  • Abiomed Issues Update on Automated Impella Controllers Due to Software Error ↗

Related Humanexa pages

  • Abiomed Issues Update on Automated Impella Controllers Due to Software Error →

Related signals

Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval

Company

BIOCODEX SA

Asset

DIACOMIT

Indication

Neurology / Epilepsy

Status

Approved

Signal Score

8.2

Regulatoryhigh signal

FDA Accepts Supplement for DIACOMIT (Stiripentol) by BIOCODEX SA

The FDA has accepted a supplemental application for DIACOMIT (Stiripentol) submitted by BIOCODEX SA.

July 4, 2026Read signal →
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval

Company

Mylan Labs

Asset

FDA

Indication

Oncology / Bone Health

Status

Approved

Signal Score

8.2

Regulatoryhigh signal

FDA Accepts Supplement Application for Zoledronic Acid by Mylan Labs

The FDA has accepted the supplemental application ANDA205254 for Zoledronic Acid submitted by Mylan Labs.

July 4, 2026Read signal →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.